Milestone Pharma Q2 2023: cash $87.6M, NDA for etripamil due Oct 2023

Milestone Pharmaceuticals Inc.

Cash, equivalents & short-term investments of $87.6M; runway into mid-2025.
NDA submission for etripamil nasal spray (PSVT) planned for October 2023.
Enrollment complete in Phase 2 ReVeRA trial (AFib-RVR); topline data Q4 2023.
Operating loss Q2 2023: $16.4M vs $16.8M in Q2 2022; R&D expense down to $8.6M.
Commercial expense rose to $3.4M in Q2 2023 from $2.2M a year earlier.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Milestone Pharmaceuticals Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023, which also provided a clinical and corporate update. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Milestone Pharmaceuticals Inc. reported the six months ended June 30, 2023 results: net income operating loss was $31.9 million.

Period: the six months ended June 30, 2023
Net income: operating loss was $31.9 million
Result: reported results

Exact text from the filing

For the six months ended June 30, 2023, Milestone's operating loss was $31.9 million, compared to $30.9 million in the prior year period.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089566

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.